Category: Government
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
Protect Funding for Lung Cancer and ALK-positive Cancer Research
ATLANTA, February 20, 2025 – The ALK Positive organization stands with patients, families, healthcare providers, researchers, and the broader medical community in our mission to increase survival for those at risk, diagnosed, and living with ALK-positive cancer. We are deeply concerned with the devastating impact that severely and suddenly reducing the budget of the National…
-
RAISE YOUR VOICE AS A CANCER PATIENT: Advocacy Letter Template
Dear Senator (or Congress woman/man) XXXXX, As one of your constituents from XXXXXX, I wanted to let you know that I am deeply concerned about the current administration’s funding cuts to NIH. For the past XXX years I have been living with stage 4 lung cancer – ALK positive – a subtype that has FDA…
-
FDA approves crizotinib for ALK-positive inflammatory myogibroblastic tumor
On July 14, 2022, the Food and Drug Administration approved crizotinib (Xalkori, Pfizer Inc.) for adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). The safety and efficacy of crizotinib were evaluated in two multicenter, single-arm, open-label trials that included 14…
-
Revival of Cancer Moonshot initiative announced by President Biden
In February 2022, President Biden announced and laid out an ambitious agenda to boost and speed up the fight against cancer, including a national year of action on cancer screening and a new Cancer Cabinet to drive progress government-wide. President Biden announced a revival of his audacious 2016 initiative – Cancer Moonshot – that is designed…